consolidation chemotherapy
Phase 3Small molecule
consolidation chemotherapy is one of 57 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.
2
Indications
9
Total Trials
3
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Neupogen
EEastern Cooperative Oncology Group
Phase 3
Alkeran
AApotex Inc.
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lenograstim
SanofiPhase 3
Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Daunorubicin or Idarubicin
NovartisPhase 3
Azacitadine
AbbViePhase 3
consolidation chemotherapy
SShenzhen People's Hospital
Phase 3
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally-advanced Rectal Cancer3 trials
Total Neoadjuvant Therapy2 trials
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Recruiting·—·Phase 2/3·NCT06758830·400 enrolled
Total Neoadjuvant Therapy in Rectal Cancer Treatment
Unknown status·SState Scientific Centre of Coloproctology, Russian Federation·Phase 4·NCT04747951·280 enrolled
Chemoradiotherapy1 trial
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
Unknown status·—·Phase 2·NCT04664504·150 enrolled
Myeloid Neoplasm1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for consolidation chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShenzhen People's Hospital